NCT07032285 (CIRTUSARC) is a Phase 2 clinical trial of Cirtuvivint in Soft Tissue Sarcoma (STS), sponsored by Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas.

What drugs are being tested in NCT07032285?

Interventions in NCT07032285: Cirtuvivint.

What condition does NCT07032285 study?

NCT07032285 studies Soft Tissue Sarcoma (STS).

Is NCT07032285 still recruiting?

NCT07032285 is currently recruiting now. Last updated 6 April 2026.

Last reviewed 2026-04-06 · How we verify

NCT07032285: CIRTUSARC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas

Recruiting now Phase 2 Last updated 6 April 2026

What this trial tests

Phase 2 trial testing Cirtuvivint in Soft Tissue Sarcoma (STS) in 25 participants. Currently enrolling.

Timeline

15 January 2025

Primary endpoint
30 April 2027

30 July 2027

Quick facts

Lead sponsor	Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	15 January 2025
Primary completion	30 April 2027
Estimated completion	30 July 2027
Sites	1 location across Spain

Drugs / interventions tested

Cirtuvivint — full drug profile →

Conditions studied

Soft Tissue Sarcoma (STS) — all drugs for Soft Tissue Sarcoma (STS) →

Sponsor

Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas — full company profile →

Who can join

Adults 16 to 70, any sex, with Soft Tissue Sarcoma (STS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a Phase 2 clinical trial of the drug cirtuvivint as a second-line treatment for advanced soft tissue sarcomas. The study is being conducted in Spain and is expected to enroll approximately 25 patients in total. The primary objective of this Phase 2 study is to evaluate the efficacy of treatment with cirtuvivint. Cirtuvivint is an anti-cancer medication developed by the U.S. company Biosplice Therapeutics, Inc. This drug is an inhibitor of the enzymes CLK1-4 and DYRK1-4 (molecules involved in the cell cycle) and is administered as oral tablets. This product is still under investigation and has not yet been approved in Europe.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Cirtuvivint

Trials testing the same drug.

NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT06484062 — Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute M · Phase 1 · recruiting

Other recruiting trials for Soft Tissue Sarcoma (STS)

Currently open trials in the same condition.

NCT07173972 — Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. · Phase 2 · recruiting
NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
NCT06980259 — Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma · NA · recruiting
NCT06815666 — BAL Fluid Biomarkers in Sarcoma · Phase 2 · recruiting
NCT06848582 — Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study · NA · recruiting

Other Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas trials

Trials by the same sponsor.

NCT06114004 — Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07032285 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Last refreshed: 6 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07032285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing